© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
The blood test identifies biomarkers that could make patients eligible for targeted therapies.
More than 40% of people treated with the PARP inhibitor saw tumor shrinkage.
Most people who received Rubraca maintenance therapy experienced tumor regression or had stable disease.
Rubraca shrank tumors and lowered PSA levels in men with advanced prostate cancer.
Study showed patients receiving rucaparib had significant improvement in progression-free survival.
Talazoparib may offer an additional option for women with BRCA gene mutations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
